Robert Carroll

Experience

• 

  Eli Lilly

  Jan 1998 - Jan 1999

  Scientist

  • Quality Control Laboratories (cGMP). HPLC, FTIR, UV, KF, dissolution, disintegration and titrimetric analysis. Equipment calibration to BP/USP standards.

• 

  GlaxoSmithKline

  Jan 2000 - Jan 2002

  Scientist

  Synthetic Chemist• Development of synthetic routes to active pharmaceutical ingredients: Robustness testing and optimisation of existing methodologies. • Scale up of methodologies from lab through to pilot plant scale. • Statistical experimental design work.Analytical Chemist• Identification and structure elucidation of unknown compounds.• Method development and validation (HPLC, GC, CE, ICP, KF).• Analysis of intermediates and final drug substance to cGMP standards. Show less

• 

  TDC Consulting and Custom Synthesis

  Jan 2005 - Jan 2007

  Technical Lead

  Leading consulting projects and providing solutions for a wide variety of pharma, life science and speciality chemical businesses.

• 

  Pfizer

  Jan 2008 - Jan 2011

  • Researching and planning: Offering the customer a range of options that balance speed, risk and cost.• Managing project deliverables and timelines.• Problem Solving/Innovation: Fast, focused and fit for purpose problem solving. This ranges from simple ‘fixes’ to riskier, high return on investment, innovative solutions delivered in a tight timeframe. Covers all aspects of the projects development.• Using resources: Leveraging collective experience to problem solve. Make best use of all available resources – intellectual, technological, facilities.• Flexibility / Change Agility: Fast response to project challenges/remapping and changing project priorities at short notice (portfolio demand change / attrition).• Lead and facilitate: Cross line application of knowledge (own and experts) and problem solving skills to define issues and identify the opportunities. Framing / defining the problem – understanding what’s essential to success and what is ‘nice to have’. Show less • Responsible for leading projects in the rapid development of Discovery synthetic routes to support delivery of pre-clinical, Phase 1 and Phase 2 clinical API supplies (0.5 - 60 kg scale).• Preparation of regulatory documentation, effective technology transfer to pilot plant facilities, working with analysts, formulators, clinicians, toxicologists and other key line functions. • Analysis of individual development portfolio projects in order to support decision making and propose resource allocation options. Show less

  • Principal Scientist/Project Lead

    Jan 2011 - Jan 2011

  • Senior Scientist

    Jan 2008 - Jan 2011
• 

  Mercury Capital Advisors

  Jan 2011 - Jan 2017

  Vice President, European Distribution

  Mercury Capital Advisors Group is a leading global private fund raising and investment advisory firm. Established in 2009 and continuing efforts that began at Merrill Lynch in 1981, Mercury Capital Advisors assists private equity, real estate, infrastructure, venture capital, distressed, mezzanine, secondary and other third-party managers in the capital raising process. The Firm also assists general partner and limited partner clients in other related activities such as fund raising advisory, co-investment and other direct deal placement, agency of secondary sales of limited partnership interests, placement of PIPES, and other areas in which the Firm has significant expertise.With offices in New York, Boston, Los Angeles, London, Tokyo and Singapore, and exclusive distribution partners in Bermuda and Latin America, the firm maintains strong relationships with a broad range of the world’s pre-eminent institutional investors, including sovereign wealth funds, corporate and public pension plans, insurance companies, endowments, family offices, foundations, funds of funds, and consultants.Since 2003, professionals now at Mercury Capital Advisors have successfully completed fundraisings for over 100 funds, ranging from $200 million to over $10 billion, with more than $110 billion in aggregate commitments. The sources of capital for these transactions are globally diverse, with investor representation from the Americas, Europe, the Middle East, Asia, and Australia. Show less

• 

  PwC

  Jan 2017 - Jan 2020

  Co-Founder of PwC's Global Fund Advisory Platform, GFAP, which serves private equity clients both in their fundraising processes and in executing platform plays such as JVs and strategic alliances. GFAP leverages PwC's presence in 157 countries which provides connectivity with LP and GP communities across the globe as well as the market insights of our sector focused professionals in PwC's 15,000 person Deals business, the largest Deals business in the world. These unique resources enable GFAP to assist our clients in managing the smooth preparation and execution of a fundraising process and provide unparalleled access and understanding of the Alternative Asset universe. Show less

  • Global Deals Origination

    Jan 2019 - Jan 2020

  • Senior Director, Global Fund Advisory Platform

    Jan 2017 - Jan 2020
• 

  Sofinnova Partners

  Jan 2020 - Dec 2024

  Partner, Head of Investor Relations and Responsible Investment Strategy

  During my time at Sofinnova, AuM was doubled to over €4bn and a comprehensive ESG framework developed and integrated with the firms operations.https://www.businesswire.com/news/home/20250303057153/en/Sofinnova-Partners-Raises-1.2-Billion-to-Fuel-the-Next-Wave-of-Life-Sciences-InnovationSofinnova Partners is a leading European venture capital firm specialised in Life Sciences, with offices in Paris, London and Milan. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies through 7 focused strategies, with a 50+ year track record of creating market leaders around the globe. Show less

• 

  POLARIS Investments

  Jan 2025 - now

  Managing Partner

  POLARIS is a Zurich and Vaduz based placement agent specialized in marketing and fund distribution for alternative investment managers within private markets and liquid alternatives.Since 2008 we support successful asset managers in their market entry, fundraising and client focused after-sales activities with institutional investors in Europe. We work with an exclusive group of asset managers worldwide, whom we select through an in-depth due diligence process together with our senior advisors and external investment consultants.We are regulated by the Financial Market Authority Liechtenstein (FMA), are a member of the German Bundesverband Alternative Investments e.V. (BAI) and a signatory to the UNPRI. Show less